Monoclonal antibodies targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) or its associated programmed cell death ligand 1 (PD-L1) have since been approved as monotherapies or in combination with existing treatments for various cancer types [23]. Here, CTLA4 is linked to cancer.